Example report. Made from Leslie Knope's DNA data so you can see what yours will look like. Get your own report

Oncology · ChemotherapiesExample report

Belinostat

Beleodaq

Use as directed

Your body may process this drug a little more slowly. The FDA has no special advice for this, so the usual dose is used.

The genes behind this label

The guidelines read one gene for belinostat. Each card shows the two copies this person inherited and what they mean.

UGT1A1*1/*28+*60+*80

Intermediate metabolizer

One copy works and one works less well.

Clears bilirubin and some drugs, such as the cancer drug irinotecan.

This result doesn't change the label.

What the guidelines say

What each guideline says about your result.

UGT1A1Intermediate metabolizer

FDA drug label

See the FDA table (U.S. Food and Drug Administration, opens in a new tab)

In plain words: Your body may process this drug a little more slowly. The FDA has no special advice for this, so the usual dose is used.
What it means: No FDA guidance for your genotype
What the label suggests: Initiate therapy with recommended starting dose.

About belinostat

Belinostat (Beleodaq) is an intravenous cancer drug for adults with peripheral T-cell lymphoma (PTCL) that has come back or has not responded to earlier treatment.

Used for: Relapsed or refractory peripheral T-cell lymphoma in adults (accelerated approval)

Others in oncology

Compare all 13 oncology

And 4 more

Don't change a dose on your own. Bring this report to your prescriber or pharmacist. They can weigh it with everything else they know about you.

Back to the example report